Emergency BU Alert Boston University's Charles River and Medical Center Campuses will be closed all day Tuesday, January 27, 2015. BU Medical Campus CLOSED Tuesday, Jan. 27, 2015 Boston University Medical Campus will be closed Tuesday, Jan. 27. All normal academic and administrative activities have been canceled. Employees in essential services should report as scheduled. Essential services include, but are not limited to Public Safety, Facilities Management, Emergency Patient Treatment, Office of Environmental Health and Safety, Occupational and Environmental Medicine, and Mail Service. Medical, PA and GMS students who are assigned to inpatient services or clinics are expected to be present, if possible. Students who are assigned to outpatient services should check with their course directors or the policy at the clinical site. For the very latest information, please go to BU Today at http://www.bu.edu/today and the Emergency Communications page at http://www.bu.edu/ehs/comm

Research

Training Program in Inflammatory Diseases Research

T-PID provides a multidisciplinary background for trainees in inflammatory disorders coupled with intensive laboratory training in a particular research topic. The program provides predoctoral and postdoctoral trainees with a solid academic background in immunology with emphasis on multi disciplinary approaches to study common mechanisms of inflammation.

Faculty research interests encompass three broad research areas including 1) Pathogen induced inflammation; 2) Chronic non-communicable inflammatory disorders; and 3) Therapeutics and preventative strategies.

 

 

PID

 

Figure: Inflammatory Disease and Therapeutics. This figure is included as an outline of the general concepts and organization of the inflammatory process that investigators included in this training grant proposal investigate. Each letter denotes a specific topic we will emphasize and an area where therapeutics have an impact, both in enhancing or suppressing the inflammatory process that can help immunity to diseases or to dampen an over exuberant immune response associated with inflammation.  Specific examples include the following:  (A and B) Use of immune adjuvants to enhance immunity to vaccines, use of TLR ligands to induce innate immune responses to suppress disease i.e. CpG DNA for infectious diseases, BCG for bladder cancer, blockade of innate immune responses induced by pattern recognition receptor ligands, i.e. sepsis, lupus; (C) Use of inflammatory cytokines to enhance immunity to pathogens, blockade of TNF in autoimmune disease, i.e. rheumatoid arthritis, inflammatory bowel disease; (D) Use of adjuvants to increase costimulatory activity; and (E) T cell suppression in transplants.